Chen Yi-Liang', Feng Wei-Ju, Zhang Xiao-Li
Acupuncture-Moxibustion and Massage Department, People's Hospital of Yizheng City, Yizheng 211400, Jiangsu Province, China.
Zhongguo Zhen Jiu. 2012 Mar;32(3):215-8.
To evaluate the therapeutic effect of Parkinson's disease combined with overactive bladder syndrome (GAB) treated with combined therapy of oral administration of Tolterodine with low dose and electroacuponcture.
Sixty cases of Parkinson's disease combined with GAB were randomly divided into a combined acupuncture and medication group (group A) and a medication group (group B), 30 cases in each group. In both groups, Madopar basic doses were same, and anticholinergic agents such as Artane were stopped. In group A, Tolterodine was orally taken for 1 mg, twice a day; Baihui (GV 20), Sishengcong (EX-HN 1) and Yintang (EX-HN 3) were punctured with electroacupuncture, once a day. In group B, Tolterodine was orally taken for 2 mg, twice a day. After 6 weeks, the changes of urination and UPDRS III scores were observed, and the adverse reactions were recorded in both groups.
After treatment, the frequency of average urination of 24 hours, frequency of incontinence of 24 hours and average urine volume at a time were obviously improved (all P < 0. 01), of which, the above items in group A were superior to those in group B (all P < 0. 05) the UPDRSIII score in group A was superior to that in group B (P < 0.05). The adverse reactions in group A were less than those in group B.
The therapeutic effect of Parkinson' s disease combined with GAB treated with combined therapy of Tolterodine with low dose and electroacupuncture is superior to that of complete dose of Tolterodine with oral administration, with less adverse reactions. And it also can improve the motor symptom of Parkinson's disease patients.
评估低剂量口服托特罗定联合电针治疗帕金森病合并膀胱过度活动症（GAB）的疗效。
将60例帕金森病合并GAB患者随机分为针药联合组（A组）和药物组（B组），每组30例。两组美多芭基础剂量相同，停用安坦等抗胆碱能药物。A组口服托特罗定1mg，每日2次；电针针刺百会（GV 20）、四神聪（EX-HN 1）、印堂（EX-HN 3），每日1次。B组口服托特罗定2mg，每日2次。6周后，观察两组排尿情况及帕金森病统一评分量表（UPDRS）Ⅲ评分变化，并记录不良反应。
治疗后，两组患者24小时平均排尿次数、24小时尿失禁次数及单次平均尿量均明显改善（均P<0.01），其中A组上述指标均优于B组（均P<0.05）；A组UPDRSⅢ评分优于B组（P<0.05）。A组不良反应少于B组。
低剂量托特罗定联合电针治疗帕金森病合并GAB的疗效优于单纯口服足量托特罗定，不良反应少，且能改善帕金森病患者的运动症状。
